10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

NCOA3 Antibody (N-term)

Affinity Purified Rabbit Polyclonal Antibody (Pab)
Catalog # AP19843a

Specification

NCOA3 Antibody (N-term) - Product Information

Application	**WB,E**
Primary Accession	Q9Y6Q9
Other Accession	Q9EPU2, NP_001167559.1
Reactivity	**Human**
Predicted	**Rat**
Host	**Rabbit**
Clonality	**Polyclonal**
Isotype	**Rabbit IgG**
Antigen Region	**344-372**

NCOA3 Antibody (N-term) - Additional Information

Gene ID 8202

Other Names
Nuclear receptor coactivator 3, NCoA-3, ACTR, Amplified in breast cancer 1 protein, AIB-1, CBP-interacting protein, pCIP, Class E basic helix-loop-helix protein 42, bHLHe42, Receptor-associated coactivator 3, RAC-3, Steroid receptor coactivator protein 3, SRC-3, Thyroid hormone receptor activator molecule 1, TRAM-1, NCOA3, AIB1, BHLHE42, RAC3, TRAM1

Target/Specificity
This NCOA3 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 344-372 amino acids from the N-terminal region of human NCOA3.

Dilution
WB~~1:1000
E~~Use at an assay dependent concentration.

Format
Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.

Storage
Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

Precautions
NCOA3 Antibody (N-term) is for research use only and not for use in diagnostic or therapeutic procedures.

NCOA3 Antibody (N-term) - Protein Information

10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

Name NCOA3

Synonyms AIB1, BHLHE42, RAC3, TRAM1

Function Nuclear receptor coactivator that directly binds nuclear receptors and stimulates the transcriptional activities in a hormone- dependent fashion. Plays a central role in creating a multisubunit coactivator complex, which probably acts via remodeling of chromatin. Involved in the coactivation of different nuclear receptors, such as for steroids (GR and ER), retinoids (RARs and RXRs), thyroid hormone (TRs), vitamin D3 (VDR) and prostanoids (PPARs). Displays histone acetyltransferase activity. Also involved in the coactivation of the NF-kappa-B pathway via its interaction with the NFKB1 subunit.

Cellular Location
Cytoplasm. Nucleus. Note=Mainly cytoplasmic and weakly nuclear. Upon TNF activation and subsequent phosphorylation, it translocates from the cytoplasm to the nucleus

Tissue Location
Widely expressed. High expression in heart, skeletal muscle, pancreas and placenta. Low expression in brain, and very low in lung, liver and kidney

NCOA3 Antibody (N-term) - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Western Blot
- Blocking Peptides
- Dot Blot
- Immunohistochemistry
- Immunofluorescence
- Immunoprecipitation
- Flow Cytomety
- Cell Culture

NCOA3 Antibody (N-term) - Images



NCOA3 Antibody (N-term) (Cat. #AP19843a) western blot analysis in HL-60 cell line lysates (35ug/lane).This demonstrates the NCOA3 antibody detected the NCOA3 protein (arrow).

NCOA3 Antibody (N-term) - Background

The protein encoded by this gene is a nuclear receptor coactivator that interacts with nuclear hormone receptors to enhance their transcriptional activator functions. The encoded protein has histone acetyltransferase activity and recruits p300/CBP-associated factor and CREB binding protein as part of a multisubunit coactivation complex. This protein is initially found in the cytoplasm but is translocated into the nucleus upon phosphorylation. Several transcript variants encoding different isoforms have been found for this gene. In addition, a polymorphic repeat region is found in the C-terminus of the encoded protein.

NCOA3 Antibody (N-term) - References

Bailey, S.D., et al. Diabetes Care 33(10):2250-2253(2010)
Cai, D., et al. Cancer Res. 70(16):6477-6485(2010)
Kovanen, L., et al. Alcohol Alcohol. 45(4):303-311(2010)
Karmakar, S., et al. Mol. Endocrinol. 24(6):1187-1202(2010)
Kleibl, Z., et al. J. Cancer Res. Clin. Oncol. (2010) In press :